Sunguk Jang

Sunguk Jang

Auto-generated profile, based on publicly available information

Sunguk Jang

Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
SJSunguk Jang
Sunguk Jang
TSTyler Stevens
Tyler Stevens
RLRocio Lopez
Rocio Lopez
ABAmit Bhatt
Amit Bhatt
JVJohn J. Vargo
John J. Vargo

9 July 2020 in Drugs
Verified
Journal Article
Closed access
PDF file
AKAdam Kichler
Adam Kichler
SJSunguk Jang
Sunguk Jang

12 March 2021 in Drugs
Verified
Journal Article
Closed access
PDF file
SASaleh A. Alqahtani
Saleh A. Alqahtani
SJSunguk Jang
Sunguk Jang

1 February 2022 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
SJSunguk Jang
Sunguk Jang
TSTyler Stevens
Tyler Stevens
MPMansour A. Parsi
Mansour A. Parsi
ABAmit Bhatt
Amit Bhatt
AKAdam Kichler
Adam Kichler
JVJohn J. Vargo
John J. Vargo

30 September 2016 in Clinical Endoscopy
Verified
Journal Article
Open access
PDF file
AGAri Garber
Ari Garber
SJSunguk Jang
Sunguk Jang
Non-variceal upper gastrointestinal bleeding, the most common etiology of which is peptic ulcer disease, remains a persistent challenge despite a reduction in both its incidence and mortality. Both pharmacologic and endoscopic techniques have been developed to achieve hemostasis, with varying degrees of success. Among the pharmacologic therapies, proton pump inhibitors remain the mainstay of treatment, as they reduce the risk of rebleeding and requirement for recurrent endoscopic evaluation. Tranexamic acid, a derivative of the amino acid lysine, is an antifibrinolytic agent whose role requires further investigation before application. Endoscopically delivered pharmacotherapy, including Hemospray (Cook Medical), EndoClot (EndoClot Plus Inc.), and Ankaferd Blood Stopper (Ankaferd Health Products), in addition to standard epinephrine, show promise in this regard, although their mechanisms of action require further investigation. Non-pharmacologic endoscopic techniques use one of the following two methods to achieve hemostasis: ablation or mechanical tamponade, which may involve using endoscopic clips, cautery, argon plasma coagulation, over-the-scope clipping devices, radiofrequency ablation, and cryotherapy. This review aimed to highlight these novel and fundamental hemostatic strategies and the research supporting their efficacy.

Verified
Journal Article
Open access
PDF file
WYWon Jae Yoon
Won Jae Yoon
YOYul Oh
Yul Oh
CYChanghoon Yoo
Changhoon Yoo
SJSunguk Jang
Sunguk Jang
SCSeong-Sik Cho
Seong-Sik Cho
Do Hyun ParkDo Hyun Park
Do Hyun Park
Although endoscopic ultrasound-guided celiac neurolysis (EUS-CN) and percutaneous celiac neurolysis (PCN) are utilized to manage intractable pain in pancreatic cancer patients, no direct comparison has been made between the two methods. We compared the efficacy and safety of EUS-CN and PCN in managing intractable pain in such patients. Sixty pancreatic cancer patients with intractable pain were randomly assigned to EUS-CN (n = 30) or PCN (n = 30). The primary outcomes were pain reduction in numerical rating scale (NRS) and opioid requirement reduction. Secondary outcomes were: successful pain response (NRS decrease ≥50% or ≥3-point reduction from baseline); quality of life; patient satisfaction; adverse events; and survival rate at 3 months postintervention. Both groups reported sustained decreases in pain scores up to 3 months postintervention (mean reductions in abdominal pain: 0.9 (95% confidence interval (CI): −0.8 to 4.2) and 1.7 (95% CI: −0.3 to 2.1); back pain: 1.3 (95% CI: −0.9 to 3.4) and 2.5 (95% CI: −0.2 to 5.2) in EUS-CN, and PCN groups, respectively). The differences in mean pain scores between the two groups at baseline and 3 months were −0.5 (p = 0.46) and −1.4 (p = 0.11) for abdominal pain and 0.1 (p = 0.85) and −0.9 (p = 0.31) for back pain in favor of PCN. No significant differences were noted in opioid requirement reduction and other outcomes. EUS-CN and PCN were similarly effective and safe in managing intractable pain in pancreatic cancer patients. Either methods may be used depending on the resources and expertise of each institution.